RTX-400

RTX-400 is an antibody-based therapeutic candidate currently in preclinical development by Resonant Therapeutics for the treatment of diverse solid tumors. The drug targets a molecular entity described as a "downregulated regulator," which was identified using Resonant's proprietary discovery platform that focuses on functional targets within the tumor microenvironment. While the specific molecular identity of the target protein has not been publicly disclosed, the therapeutic is designed to address oncogenic processes or immune evasion mechanisms associated with the downregulation of this specific regulator. The candidate may be developed as a naked antibody, an antibody-drug conjugate (ADC), or a bispecific antibody format.